Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis.
OBJECTIVE
To assess the clinical value of squamous cell carcinoma antigen (SCCAg) in anal cancer for chemoradiotherapy (CRT) patients.


METHODS
In 24 patients with SCC of the anus, SCCAg was determined before CRT and at every follow-up visit.


RESULTS
16/24 (66.7%) had normal SCCAg and 11/16 (68.8%) achieved complete remission (CR), while 7/8 (87.5%) with elevated SCCAg achieved CR. In two patients, elevated SCCAg was observed after radiotherapy. One was false-positive and one was true-positive leading to diagnosis of metachronous recurrent and metastatic disease after interim CR.


CONCLUSIONS
SCCAg was inappropriate to predict the clinical outcome but can provide additional information on the regular follow-up examinations to detect a relapse.
Department of Radiation Oncology, MHH, Hannover, Germany Henkenberens.christoph@mh-hannover.de.
Christoph
C
Henkenberens
Department of Internal Medicine, Robert-Koch Hospital, Gehrden, Germany.
Hakan
H
Toklu
End- und Dickdarmzentrum Hannover (edh), Hannover, Germany.
Carsten
C
Tamme
Department of Radiation Oncology, MHH, Hannover, Germany.
Frank
F
Bruns
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D001005:Anus Neoplasms / Q000276:immunology / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D015843:Serpins / Q000032:analysis*
D000951:Antigens, Neoplasm; D015843:Serpins; C051072:squamous cell carcinoma-related antigen
Squamous cell carcinoma antigen (SCCAg); anal cancer; chemoradiation